Monitor the AHNS presentation on July 21, 2026, for top-line efficacy and safety data. Positive results could drive near-term interest in DRTS, but regulatory and commercialization timelines remain distant.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $7.39entry
- T+1 · 7mo ago +2.71%α +1.32% · $7.59
- T+5 · 6mo ago +39.92%α +37.93% · $10.34
- T+20 · 6mo ago +20.84%α +15.88% · $8.93
- T+60 · 4mo ago +60.89%α +58.15% · $11.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical announced that an abstract on Alpha DaRT in combination with pembrolizumab for elderly patients with head and neck cancer has been accepted for a podium presentation at the AHNS International Conference (July 18-22, 2026). This marks a strategic milestone for the company's combination therapy program, building on prior monotherapy data.
Key Facts
- Abstract accepted for podium presentation at AHNS International Conference on Head and Neck Cancer (July 21, 2026)
- Study evaluates Alpha DaRT + pembrolizumab in elderly patients with locally advanced/metastatic HNSCC
- Complete top-line data to be presented; builds on prior monotherapy safety data
- Elderly HNSCC patients have limited treatment options, representing a significant unmet need
Financial Impact
No financial data provided; potential upside if combination data is positive, but no revenue impact expected near-term
Risk Factors
- Clinical trial data may not meet expectations
- Competition from other intratumoral therapies and immunotherapies
- Regulatory approval and reimbursement uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287848 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers